TG Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated: Who Leads in Yearly Revenue?

Biotech Revenue Battle: Ligand vs. TG Therapeutics

__timestampLigand Pharmaceuticals IncorporatedTG Therapeutics, Inc.
Wednesday, January 1, 201464538000152381
Thursday, January 1, 201571914000152381
Friday, January 1, 2016108973000152381
Sunday, January 1, 2017141102000152381
Monday, January 1, 2018251453000152000
Tuesday, January 1, 2019120282000152000
Wednesday, January 1, 2020186419000152000
Friday, January 1, 20212771330006689000
Saturday, January 1, 20221962450002785000
Sunday, January 1, 2023131314000233662000
Loading chart...

Data in motion

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Ligand Pharmaceuticals Incorporated has consistently outperformed TG Therapeutics, Inc. in terms of annual revenue. From 2014 to 2023, Ligand's revenue surged by approximately 103%, peaking in 2021 with a remarkable 278 million dollars. In contrast, TG Therapeutics experienced a significant revenue spike in 2023, reaching 234 million dollars, a dramatic increase from its previous years of modest earnings.

This data highlights Ligand's steady growth trajectory, while TG Therapeutics' recent revenue leap suggests a potential breakthrough or strategic shift. Investors and industry watchers should keep an eye on these trends, as they may signal future market dynamics and investment opportunities in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025